Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Carcinoma × dostarlimab × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Uterine Cervical Neoplasms 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Rectal Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Rhabdomyosarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Multiple Myeloma 1 Hodgkin Disease 1 Hepatoblastoma 1 Glioblastoma 1 Fibrolamellar hepatocellular carcinoma 1 Fallopian Tube Neoplasms 1 Ependymoma 1 Diffuse Intrinsic Pontine Glioma 1 Colorectal Neoplasms 1 Carcinoma, Neuroendocrine 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 9 Cisplatin 9 Carboplatin 7 Paclitaxel 6 durvalumab 5 Pemetrexed 4 Magnetic Resonance Spectroscopy 4 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 4 osimertinib 3 Taxes 3 Specimen Handling 3 Nivolumab 3 Gemcitabine 3 Docetaxel 3 Bevacizumab 3 cabozantinib 2 atezolizumab 2 Sunitinib 2 Radiotherapy, Intensity-Modulated 2 Radiation 2 Platinum 2 Ipilimumab 2 Immunoglobulin G 2 Disulfides 2 CP protocol 2 1,2-diaminocyclohexaneplatinum II citrate 2 trifluridine tipiracil drug combination 1 tremelimumab 1 relatlimab 1 regorafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06317311 2025-07-25

RUBY-J

GlaxoSmithKline

Phase 2 Active not recruiting

Carcinoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡